INTRODUCTION {#s1}
============

Breast cancer is a complex multifactorial disease with unclear etiology. DNA damage and genomic instability, a potential risk of breast cancer, are induced by common environmental factors \[[@R2]\]. However, we are born with a system to protect our genome from DNA damage and correct for damage after it occurs, including nucleotide excision repair (NER), mismatch repair (MMR), bases excision repair (BER), transcription-coupled repair (TCR), and double-strand DNA break repair systems \[[@R3]\].

NER repairs damage introduced by ultraviolet (UV) radiation, products of organic combustion, intrastrand DNA cross-links, heavy metals, and oxidative stress. Several proteins, including ERCC1, XPA, XPB/ERCC3, XPC, XPD/ERCC2, ERCC4/XPF, ERCC5/XPG, and PE/DDB1, are involved in the repair process, maintaining genome integrity to prevent carcinogenesis. The process of NER comprises several distinct steps, including DNA damage recognition, DNA damage demarcation, damaged DNA incision, repair patch synthesis, and ligation. Polymorphisms in NER pathway genes have been associated with increased risk for a number of cancers \[[@R4]\] \[[@R5]--[@R8]\].

Breast cancer patients and their relatives tend to have constitutively low NER levels in their peripheral blood lymphocytes \[[@R9], [@R10]\]. Moreover, polymorphisms in NER pathway genes have been linked to breast cancer risk in studies conducted on patients of some ethnicities. However, the conclusions have been inconsistent \[[@R11]--[@R14]\]. Among the Chinese population, studies have reported correlations between polymorphisms in NER pathway genes and breast cancer risk, but to date, there is no systematic investigation on the genetic susceptibility of the NER pathway in breast cancer \[[@R15]--[@R19]\]. To provide a more comprehensive understanding of the relationships between specific polymorphisms in the NER pathway genes (Table [1](#T1){ref-type="table"}) on the carcinogenesis of breast cancer, we performed a breast cancer risk association study and a meta-analysis.

###### Candidate genes and polymorphisms

  Gene          rs \#       Chromosome     Allele (major/minor)   Position                        HWE in controls
  ------------- ----------- -------------- ---------------------- ------------------------------- -----------------
  *XPA*         rs1800975   9:97697296     G/A                    5\' non-coding region (-4A/G)   0.118/2.445
  *ERCC1*       rs11615     19:45420395    C/T                    Exon 4 (Asn118Asn)              0.509/0.436
  *XPC*         rs2228000   3:14158387     C/T                    Exon 9 (Ala499Val)              0.498/0.460
  *XPC*         rs2228001   3:14145949     A/C                    Exon 16 (Gln939Lys)             0.267/1.231
  *ERCC2/XPD*   rs238406    19:45365051    G/T                    Exon 6 (Arg156Arg)              0.766/0.088
  *ERCC2/XPD*   rs1799793   19:45364001    G/A                    Exon 10 (Asp 312 Asn)           0.101/2.687
  *ERCC2/XPD*   rs50872     19:45359191    C/T                    Intron 12                       0.945/0.005
  *ERCC2/XPD*   rs13181     19:45351661    T/A                    Exon 23 ( Lys751 Gln)           0.716/0.132
  *ERCC2/XPD*   rs3810366   19:45370684    C/G                    Promoter (-114)                 0.099/2.728
  *ERCC4/XPF*   rs1799801   16:13948101    T/C                    Exon 11 (Ser835Ser)             0.619/0.247
  *ERCC5/XPG*   rs17655     13:102875652   C/G                    Exon 15 (His1104Asp)            0.077/3.137

RESULTS {#s2}
=======

None of the tested polymorphisms deviated from Hardy-Weinberg equilibrium (HWE) in controls (Table [1](#T1){ref-type="table"}). There were no significant differences in the age and menopausal status among cases and controls (Table [2](#T2){ref-type="table"}).

###### Clinical characteristics of the participants

                               Cases, *n* (%)   Controls, *n* (%)   *P* value
  ---------------------------- ---------------- ------------------- -------------------------------------------
  **Age (mean ± SD)**          52.85 ± 10.77    52.67 ± 10.78       0.799[^\*^](#tfn001){ref-type="table-fn"}
  **Menopausal status**                                             0.110
   Pre-                        206 (45.78)      220 (51.16)         
   Post-                       244 (54.22)      210 (48.84)         
  **Tumor size (T1-T4)**                                            
   T1-T2                       312(69.33)                           
   T3-T4                       138(30.67)                           
  **Tumor grade (G1-G3)**                                           
   G1                          86(19.11)                            
   G2                          238(52.89)                           
   G3                          126(28.00)                           
  **Lymph node involvement**                                        
   Yes                         235(52.22)                           
   No                          215(47.78)                           
  **ER**                                                            
   Positive                    278(61.78)                           
   Negative                    172(38.22)                           
  **PR**                                                            
   Positive                    238(52.89)                           
   Negative                    212(47.11)                           
  **HER-2**                                                         
   Positive                    353(78.44)                           
   Negative                    97(21.55)                            

Independent t test applied to age; ER, estrogen receptor; HER-2, human epidermal growth factor receptor-2; PR, progesterone receptor.

The genotype distribution in the two groups and their subgroups of menopausal status are presented in Table [3](#T3){ref-type="table"}. The result showed that *ERCC1* rs11615, *XPC* rs2228000, and *ERCC2/XPD* rs50872 carriers have a higher breast cancer risk in the whole study population. Stratified analysis of menopausal status revealed that *XPC* rs2228000 has a higher breast cancer risk in the premenopausal sub-cohort. While in the postmenopausal sub-cohort, *ERCC1* rs11615 and *ERCC2/XPD* rs50872 were associated with increased breast cancer risk. On the contrary, *XPA* rs1800975 and *XPC* rs2228001 were associated with decreased breast cancer risk.

###### Distribution of the genotypes in the participants and sub-groups

  Genotype                All participants   Premenopause      Postmenopause                                                                   
  ----------------------- ------------------ ----------------- --------------- --------- ----------------- ------- --------- ----------------- -------
  *XPA* rs1800975                                                                                                                              
  GG                      115/93             Reference                         47/55     Reference                 68/38     Reference         
  GA                      235/231            0.82(0.59,1.14)   0.245           106/114   1.06(0.66,1.71)   0.805   129/117   0.63(0.39,1.01)   0.057
  AA                      100/106            0.77(0.52,1.13)   0.186           53/51     1.21(0.70,2.10)   0.489   47/55     0.48(0.27,0.83)   0.009
  GA/AA                   335/337            0.81(0.59,1.11)   0.185           159/165   1.11(0.71,1.74)   0.646   176/172   0.59(0.37,0.92)   0.020
  Additive model          450/430            0.88(0.73,1.07)   0.198           206/220   1.10(0.84,1.45)   0.488   244/210   0.70(0.53,0.92)   0.012
  *ERCC1* rs11615                                                                                                                              
  CC                      230/261            Reference                         108/128   Reference                 122/133   Reference         
  CT                      195/151            1.45(1.10,1.92)   0.009           86/86     1.17(0.79,1.74)   0.430   109/65    1.80(1.21,2.68)   0.004
  TT                      25/18              1.56(0.83,2.94)   0.168           12/6      2.32(0.84,6.41)   0.104   13/12     1.18(0.52,2.69)   0.700
  CT/TT                   220/169            1.46(1.11,1.91)   0.006           98/92     1.25(0.85,1.83)   0.260   122/77    1.69(1.16,2.47)   0.007
  Additive model          450/430            1.36(1.08,1.71)   0.009           206/220   1.29(0.93,1.80)   0.131   244/210   1.42(1.04,1.95)   0.030
  *XPC* rs2228000                                                                                                                              
  CC                      201/228            Reference                         86/116    Reference                 115/112   Reference         
  CT                      198/174            1.31(0.99,1.73)   0.061           94/85     1.51(1.01,2.26)   0.048   104/89    1.15(0.78,1.69)   0.481
  TT                      51/28              2.16(1.3,3.57)    0.003           26/19     1.85(0.96,3.57)   0.065   25/9      2.69(1.20,6.02)   0.016
  CT/TT                   249/212            1.42(1.09,1.86)   0.010           120/104   1.57(1.07,2.30)   0.022   129/98    1.30(0.90,1.88)   0.170
  Additive model          450/430            1.39(1.13,1.72)   0.002           206/220   1.41(1.06,1.88)   0.020   244/210   1.37(1.02,1.85)   0.038
  *XPC* rs2228001                                                                                                                              
  AA                      193/161            Reference                         86/91     Reference                 107/70    Reference         
  AC                      195/213            0.76(0.57,1.01)   0.060           90/100    0.96(0.64,1.45)   0.850   105/113   0.61(0.41,0.91)   0.015
  CC                      62/56              0.91(0.60,1.38)   0.649           30/29     1.08(0.60,1.96)   0.791   32/27     0.76(0.42,1.38)   0.364
  AC/CC                   257/269            0.79(0.60,1.04)   0.090           120/129   0.99(0.67,1.45)   0.944   137/140   0.64(0.44,0.94)   0.022
  Additive model          450/430            0.90(0.74,1.09)   0.275           206/220   1.02(0.77,1.34)   0.909   244/210   0.79(0.60,1.04)   0.098
  *ERCC2/XPD* rs238406                                                                                                                         
  GG                      128/128            Reference                         55/62     Reference                 73/66     Reference         
  GT                      227/216            1.05(0.77,1.43)   0.763           108/111   1.09(0.70,1.71)   0.700   119/105   1.01(0.66,1.55)   0.961
  TT                      95/86              1.12(0.76,1.64)   0.577           43/47     1.05(0.60,1.84)   0.855   52/39     1.19(0.69,2.03)   0.534
  GT/TT                   322/302            1.07(0.80,1.43)   0.661           151/158   1.08(0.70,1.65)   0.739   171/144   1.06(0.71,1.59)   0.772
  Additive model          450/430            1.06(0.87,1.28)   0.583           206/220   1.02(0.78,1.35)   0.866   244/210   1.08(0.83,1.41)   0.546
  *ERCC2/XPD* rs1799793                                                                                                                        
  GG                      380/367            Reference                         171/192   Reference                 209/175   Reference         
  GA                      69/63              1.05(0.72,1.52)   0.800           35/28     1.41(0.82,2.42)   0.211   34/35     0.80(0.48,1.34)   0.399
  AA                      1/0                \--               \--             0/0       \--               \--     1/0       \--               \--
  GA/AA                   70/63              1.06(0.73,1.54)   0.743           35/28     1.41(0.82,2.42)   0.211   35/35     0.82(0.50,1.37)   0.460
  Additive model          450/430            1.08(0.75,1.56)   0.683           206/220   1.41(0.82,2.42)   0.211   244/210   0.86(0.52,1.41)   0.543
  *ERCC2/XPD* rs50872                                                                                                                          
  CC                      269/290            Reference                         130/151   Reference                 139/139   Reference         
  CT                      160/126            1.35(1.01,1.79)   0.044           66/61     1.27(0.83,1.93)   0.270   94/65     1.42(0.96,2.11)   0.081
  TT                      21/14              1.64(0.82,3.29)   0.165           10/8      1.53(0.58,4.01)   0.388   11/6      1.83(0.66,5.10)   0.245
  CT/TT                   181/140            1.38(1.04,1.81)   0.024           76/69     1.29(0.86,1.93)   0.212   105/71    1.46(0.99,2.14)   0.054
  Additive model          450/430            1.32(1.04,1.67)   0.021           206/220   1.25(0.89,1.75)   0.199   244/210   1.40(1.00,1.95)   0.048
  *ERCC2/XPD* rs13181                                                                                                                          
  TT                      361/354            Reference                         169/181   Reference                 192/173   Reference         
  GT                      86/73              1.16(0.82,1.63)   0.412           37/38     1.06(0.64,1.75)   0.824   49/35     1.26(0.78,2.03)   0.353
  GG                      3/3                0.95(0.19,4.74)   0.945           0/1       \--               \--     3/2       1.40(0.23,8.50)   0.715
  GT/GG                   89/76              1.15(0.82,1.61)   0.432           37/39     1.03(0.63,1.69)   0.915   52/37     1.27(0.79,2.02)   0.327
  Additive model          450/430            1.13(0.82,1.55)   0.472           206/220   0.99(0.61,1.62)   0.980   244/210   1.24(0.81,1.92)   0.326
  *ERCC2/XPD* rs3810366                                                                                                                        
  GG                      112/94             Reference                         55/56     Reference                 57/38     Reference         
  CG                      234/232            0.84(0.60,1.17)   0.292           107/109   1.00(0.63,1.58)   0.997   127/123   0.69(0.43,1.12)   0.134
  CC                      104/104            0.83(0.56,1.23)   0.353           44/55     0.80(0.47,1.39)   0.436   60/49     0.84(0.48,1.48)   0.545
  CG/CC                   338/336            0.84(0.61,1.15)   0.268           151/164   0.93(0.60,1.44)   0.745   187/172   0.74(0.47,1.18)   0.202
  Additive model          450/430            0.92(0.76,1.11)   0.375           206/220   0.90(0.69,1.19)   0.462   244/210   0.93(0.70,1.23)   0.598
  *ERCC4/XPF* rs1799801                                                                                                                        
  TT                      268/260            Reference                         118/136   Reference                 150/124   Reference         
  CT                      157/151            1.01(0.76,1.34)   0.949           78/69     1.31(0.87,1.97)   0.196   79/82     0.79(0.54,1.17)   0.244
  CC                      25/19              1.31(0.70,2.45)   0.399           10/15     0.76(0.33,1.77)   0.526   15/4      3.03(0.98,9.37)   0.055
  CT/CC                   182/170            1.04(0.79,1.36)   0.775           88/84     1.22(0.83,1.79)   0.324   94/86     0.90(0.62,1.31)   0.579
  Additive model          450/430            1.06(0.85,1.33)   0.593           206/220   1.08(0.79,1.47)   0.647   244/210   1.05(0.76,1.45)   0.763
  *ERCC5/XPG* rs17655                                                                                                                          
  GG                      101/107            Reference                         48/61     Reference                 53/46     Reference         
  CG                      243/233            1.09(0.79,1.52)   0.588           114/114   1.27(0.80,2.01)   0.311   129/119   0.94(0.59,1.50)   0.796
  CC                      106/90             1.22(0.82,1.80)   0.332           44/45     1.23(0.70,2.16)   0.471   62/45     1.20(0.69,2.08)   0.524
  CG/CC                   349/323            1.12(0.82,1.54)   0.464           158/159   1.26(0.81,1.95)   0.308   191/164   1.00(0.64,1.57)   1.000
  Additive model          450/430            1.11(0.91,1.35)   0.307           206/220   1.12(0.85,1.48)   0.433   244/210   1.10(0.83,1.44)   0.509

Adjusted by age and menopausal status;

Adjusted by age; Ca, case; Co, control.

Based on the observed significant associations, we then performed stratified analysis based on pathological characteristics of the breast cancer (tumor size, lymph node involvement) and expression of specific proteins in tumor tissue (PR, ER, and HER-2). Tumor size (T3-T4) was associated with all polymorphisms of interest except for *XPA* rs1800975. In addition, *ERCC1* rs11615 carriers have a high risk of breast cancer with grade 3, while *XPC* rs2228000 and *ERCC2/XPD* rs50872 are linked to a high risk for breast cancer with grades 1 and 2, respectively. For the lymph node involvement subgroup, *XPC* rs2228001 and *ERCC2/XPD* rs50872 carriers have a high risk of breast cancer with negative lymph node involvement. While *ERCC1* rs11615 and *XPC* rs2228000, were significantly associated with both negative and positive lymph node involvement subgroups (Table [4](#T4){ref-type="table"}).

###### Polymorphisms on breast cancer risk by pathological characteristics of tumor

  Genotype              Co    Tumor size (T1-T2)   Tumor size (T3-T4)   Grade (G1-G2)   Grade (G3)   Lymph node involvement(Negative)   Lymph node involvement (Positive)                                                                                                                          
  --------------------- ----- -------------------- -------------------- --------------- ------------ ---------------------------------- ----------------------------------- ----- ----------------- ------- ---- ----------------- ------- ----- ----------------- ------- ----- ----------------- -------
  *XPA* rs1800975                                                                                                                                                                                                                                                                                  
  GG                    93    77                   Reference                            38           Reference                                                              80    Reference                 35   Reference                 57    Reference                 58    Reference         
  GA                    231   167                  0.88(0.61,1.26)      0.482           68           0.71(0.45,1.14)                    0.158                               177   0.89(0.62,1.28)   0.535   58   0.65(0.40,1.06)   0.087   111   0.78(0.52,1.16)   0.216   124   0.86(0.58,1.29)   0.470
  AA                    106   68                   0.78(0.51,1.21)      0.267           32           0.74(0.42,1.27)                    0.271                               67    0.74(0.48,1.14)   0.176   33   0.80(0.46,1.40)   0.432   47    0.73(0.45,1.17)   0.188   53    0.80(0.50,1.28)   0.353
  GA/AA                 337   235                  0.85(0.60,1.20)      0.359           100          0.73(0.47,1.13)                    0.155                               244   0.85(0.60,1.20)   0.350   91   0.71(0.45,1.12)   0.139   158   0.77(0.52,1.12)   0.168   177   0.85(0.58,1.24)   0.395
  *ERCC1* rs11615                                                                                                                                                                                                                                                                                  
  CC                    261   163                  Reference                            67           Reference                                                              176   Reference                 54   Reference                 117   Reference                 113   Reference         
  TC                    151   128                  1.36(1.00,1.85)      0.054           67           1.70(1.15,2.53)                    0.008                               128   1.24(0.91,1.68)   0.171   67   2.19(1.45,3.32)   0.000   81    1.18(0.83,1.68)   0.348   114   1.75(1.26,2.44)   0.001
  TT                    18    21                   1.85(0.95,3.57)      0.069           4            0.90(0.29,2.76)                    0.850                               20    1.64(0.84,3.19)   0.147   5    1.32(0.47,3.74)   0.595   17    2.12(1.05,4.27)   0.035   8     1.00(0.42,2.38)   0.999
  TC/TT                 169   149                  1.40(1.04,1.88)      0.028           71           1.61(1.09,2.37)                    0.016                               148   1.27(0.95,1.71)   0.109   72   2.07(1.38,3.11)   0.000   98    1.27(0.91,1.78)   0.154   122   1.65(1.20,2.28)   0.002
  *XPC* rs2228000                                                                                                                                                                                                                                                                                  
  CC                    228   145                  Reference                            56           Reference                                                              141   Reference                 60   Reference                 98    Reference                 103   Reference         
  CT                    174   139                  1.28(0.94,1.74)      0.119           59           1.39(0.91,2.10)                    0.124                               149   1.41(1.04,1.91)   0.028   49   1.06(0.69,1.63)   0.782   91    1.24(0.88,1.76)   0.226   107   1.36(0.97,1.90)   0.074
  TT                    28    28                   1.69(0.95,2.99)      0.074           23           3.43(1.83,6.44)                    0.000                               34    2.08(1.20,3.60)   0.009   17   2.42(1.24,4.75)   0.010   26    2.39(1.32,4.34)   0.004   25    2.02(1.12,3.64)   0.020
  CT/TT                 202   167                  1.33(0.99,1.78)      0.058           82           1.67(1.13,2.46)                    0.010                               183   1.49(1.12,2.00)   0.007   66   1.25(0.84,1.86)   0.280   117   1.38(0.99,1.92)   0.056   132   1.45(1.05,2.00)   0.023
  *XPC* rs2228001                                                                                                                                                                                                                                                                                  
  AA                    161   127                  Reference                            66           Reference                                                              139   Reference                 54   Reference                 96    Reference                 97    Reference         
  AC                    213   139                  0.81(0.59,1.12)      0.205           56           0.64(0.42,0.96)                    0.033                               142   0.77(0.56,1.05)   0.095   53   0.73(0.48,1.13)   0.160   86    0.67(0.47,0.95)   0.026   109   0.85(0.60,1.19)   0.341
  CC                    56    46                   1.02(0.64,1.61)      0.940           16           0.68(0.36,1.27)                    0.225                               43    0.87(0.55,1.38)   0.548   19   1.00(0.54,1.85)   0.996   33    0.97(0.59,1.61)   0.916   29    0.83(0.49,1.40)   0.483
  AC/CC                 269   185                  0.86(0.64,1.16)      0.319           72           0.65(0.44,0.95)                    0.027                               185   0.79(0.59,1.06)   0.115   72   0.79(0.53,1.18)   0.252   119   0.73(0.52,1.02)   0.064   138   0.85(0.61,1.17)   0.317
  *ERCC2/XPD* rs50872                                                                                                                                                                                                                                                                              
  CC                    290   192                  Reference                            77           Reference                                                              195   Reference                 74   Reference                 126   Reference                 143   Reference         
  CT                    126   105                  1.24(0.90,1.70)      0.186           55           1.62(1.08,2.43)                    0.020                               113   1.31(0.96,1.80)   0.089   47   1.45(0.95,2.21)   0.087   79    1.42(1.00,2.03)   0.049   81    1.29(0.91,1.82)   0.154
  TT                    14    15                   1.68(0.79,3.57)      0.180           6            1.63(0.60,4.37)                    0.336                               16    1.77(0.84,3.72)   0.134   5    1.41(0.49,4.08)   0.522   10    1.69(0.73,3.91)   0.223   11    1.62(0.72,3.68)   0.247
  CT/TT                 140   120                  1.28(0.94,1.74)      0.113           61           1.62(1.09,2.39)                    0.017                               129   1.36(1.01,1.84)   0.046   52   1.44(0.96,2.17)   0.082   89    1.45(1.03,2.04)   0.032   92    1.32(0.95,1.84)   0.104

Adjusted by age and menopausal status; Ca, case; Co, control.

For tumor tissue characteristics, *XPA* rs1800975 and *ERCC2/XPD* rs50872 carriers have a high risk of breast cancer with negative expression of ER and PR. While *ERCC1* rs11615 have a high risk of ER+ and PR+ breast cancer and PR. The susceptibility of *XPC* rs2228000 to breast cancer risk was observed in both subgroups; however, there was no significant association for *XPC* rs2228001 in any subgroup (Table [5](#T5){ref-type="table"}).

###### Effects of five SNPs on breast cancer risk as stratified by expression of ER, PR, and HER-2

  Genotype              Co    ER (-)   ER (+)            PR (-)   PR (+)   HER-2 (-)         HER-2 (+)                                                                                                                          
  --------------------- ----- -------- ----------------- -------- -------- ----------------- ----------- ----- ----------------- ------- ----- ----------------- ------- ---- ----------------- ------- ----- ----------------- -------
  *XPA* rs1800975                                                                                                                                                                                                               
  GG                    93    51       Reference                  64       Reference                     61    Reference                 54    Reference                 27   Reference                 88    Reference         
  GA                    231   86       0.67(0.44,1.03)   0.067    149      0.93(0.64,1.36)   0.718       109   0.72(0.49,1.08)   0.113   126   0.93(0.62,1.39)   0.720   46   0.69(0.41,1.18)   0.177   189   0.86(0.60,1.22)   0.399
  AA                    106   35       0.60(0.36,1.01)   0.055    65       0.89(0.57,1.39)   0.602       42    0.61(0.37,0.99)   0.044   58    0.94(0.59,1.49)   0.786   24   0.78(0.42,1.45)   0.432   76    0.76(0.50,1.15)   0.196
  GA/AA                 337   121      0.65(0.44,0.98)   0.038    214      0.92(0.64,1.33)   0.670       151   0.69(0.47,1.00)   0.053   184   0.94(0.64,1.38)   0.747   70   0.73(0.44,1.20)   0.212   265   0.83(0.60,1.16)   0.284
  *ERCC1* rs11615                                                                                                                                                                                                               
  CC                    261   98       Reference                  132      Reference                     119   Reference                 111   Reference                 47   Reference                 183   Reference         
  TC                    151   70       1.23(0.85,1.78)   0.276    125      1.63(1.18,2.24)   0.003       82    1.16(0.82,1.64)   0.414   113   1.78(1.28,2.48)   0.001   48   1.73(1.10,2.72)   0.018   147   1.38(1.03,1.87)   0.034
  TT                    18    4        0.58(0.19,1.76)   0.333    21       2.28(1.17,4.44)   0.015       11    1.34(0.61,2.94)   0.463   14    1.81(0.87,3.77)   0.114   2    0.66(0.15,2.95)   0.585   23    1.80(0.94,3.44)   0.075
  TC/TT                 169   74       1.16(0.81,1.66)   0.432    146      1.68(1.24,2.29)   0.001       93    1.17(0.84,1.64)   0.352   127   1.76(1.28,2.43)   0.001   50   1.61(1.03,2.51)   0.037   170   1.41(1.06,1.88)   0.018
  *XPC* rs2228000                                                                                                                                                                                                               
  CC                    228   84       Reference                  117      Reference                     96    Reference                 105   Reference                 41   Reference                 160   Reference         
  CT                    174   67       1.06(0.72,1.54)   0.773    131      1.48(1.08,2.04)   0.016       88    1.23(0.86,1.75)   0.257   110   1.38(0.99,1.92)   0.059   41   1.32(0.82,2.12)   0.257   157   1.30(0.97,1.75)   0.082
  TT                    28    21       2.27(1.20,4.26)   0.011    30       2.15(1.22,3.78)   0.008       28    2.62(1.45,4.73)   0.001   23    1.83(1.00,3.34)   0.049   15   3.09(1.50,6.36)   0.002   36    1.93(1.12,3.31)   0.017
  CT/TT                 202   88       1.21(0.85,1.72)   0.299    161      1.58(1.16,2.14)   0.004       116   1.41(1.01,1.96)   0.045   133   1.44(1.05,1.98)   0.026   56   1.55(0.99,2.42)   0.055   193   1.39(1.04,1.84)   0.025
  *XPC* rs2228001                                                                                                                                                                                                               
  AA                    161   72       Reference                  121      Reference                     94    Reference                 99    Reference                 43   Reference                 150   Reference         
  AC                    213   79       0.81(0.55,1.19)   0.277    116      0.72(0.52,1.00)   0.051       90    0.71(0.49,1.01)   0.055   105   0.80(0.57,1.13)   0.202   42   0.74(0.46,1.20)   0.220   153   0.76(0.56,1.04)   0.085
  CC                    56    21       0.80(0.45,1.42)   0.444    41       0.97(0.60,1.55)   0.894       28    0.81(0.48,1.37)   0.436   34    0.99(0.60,1.62)   0.958   12   0.77(0.38,1.58)   0.482   50    0.94(0.60,1.47)   0.790
  AC/CC                 269   100      0.81(0.56,1.16)   0.251    157      0.77(0.57,1.05)   0.098       118   0.73(0.52,1.02)   0.066   139   0.84(0.61,1.16)   0.284   54   0.75(0.48,1.18)   0.213   203   0.80(0.60,1.07)   0.133
  *ERCC2/XPD* rs50872                                                                                                                                                                                                           
  CC                    290   89       Reference                  180      Reference                     113   Reference                 156   Reference                 58   Reference                 211   Reference         
  CT                    126   73       1.86(1.28,2.71)   0.001    87       1.10(0.79,1.53)   0.588       85    1.71(1.20,2.43)   0.003   75    1.09(0.77,1.55)   0.621   36   1.43(0.89,2.28)   0.136   124   1.33(0.98,1.81)   0.069
  TT                    14    10       2.44(1.04,5.73)   0.040    11       1.27(0.56,2.86)   0.565       14    2.61(1.20,5.68)   0.016   7     0.93(0.37,2.36)   0.882   3    1.08(0.30,3.90)   0.905   18    1.80(0.88,3.72)   0.110
  CT/TT                 140   83       1.92(1.34,2.76)   0.000    98       1.11(0.81,1.53)   0.518       99    1.80(1.28,2.52)   0.001   82    1.08(0.77,1.51)   0.658   39   1.39(0.88,2.19)   0.157   142   1.38(1.03,1.85)   0.033

Adjusted by age and menopausal status; Ca, case; Co, control.

For *ERCC2/XPD* rs238406, rs1799793, rs13181, rs3810366, *ERCC4/XPF* rs1799801, *ERCC5/XPG* rs17655, no significant association was found (Table [3](#T3){ref-type="table"}).

To confirm the results of our case study, we performed a meta-analysis involving *XPC* rs2228000, rs2228001, *XPA* rs1800975, and *ERCC1* rs11615 (Table [6](#T6){ref-type="table"}). We identified 14 studies for the meta-analysis according to the inclusion criteria. The characteristics of the selected studies are presented in [Supplemental Table S1](#SD1){ref-type="supplementary-material"}. The allele frequencies of the four polymorphisms in Asian and Caucasian populations are shown in [Supplemental Table S2](#SD1){ref-type="supplementary-material"}, indicating the allele frequencies of this study were consistent with those of the pooled data.

###### Meta-analysis of the XPC rs2228000, rs2228001, XPA rs1800975 and ERCC1 rs11615 polymorphism on breast cancer risk

  Variables               Cases/controls                                 Homozygote vs. wild type   Heterozygote vs. wild type   Dominant model   Recessive model[^d^](#tfn009){ref-type="table-fn"}                                                                                                                   
  ----------------------- ---------------------------------------------- -------------------------- ---------------------------- ---------------- ---------------------------------------------------- ------- ------- ---------------------------------------------------- ------- ------- ------------------ ------- -------
  *XPC* rs2228000                                                                                                                                                                                                                                                                                                      
  Total                   3897/4877[^a^](#tfn006){ref-type="table-fn"}   1.28(1.08-1.52)            0.004                        0.228            1.01(0.92,1.10)                                      0.867   0.291   1.02(0.89,1.17)[^c^](#tfn008){ref-type="table-fn"}   0.766   0.030   1.25(1.06, 1.47)   0.008   0.521
  **Ethnicities**                                                                                                                                                                                                                                                                                                      
  Caucasian               570/676                                        0.95(0.59,1.51)            0.811                        0.979            0.86(0.68,1.08)                                      0.196   0.983   0.87(0.69,1.09)                                      0.219   0.991   1.01(0.64,1.59)    0.981   0.990
  Asian                   1068/1052                                      1.73(1.30,2.31)            0.000                        0.384            1.26(1.05,1.51)                                      0.015   0.803   1.37(1.15,1.64)                                      0.000   0.475   1.52(1.16,1.99)    0.002   0.349
  Other                   2259/3149                                      1.13(0.89,1.43)            0.318                        0.748            0.97(0.86,1.08)                                      0.520   0.809   0.97(0.88,1.08)                                      0.597   0.557   1.14(0.90,1.43)    0.287   0.674
  **Source of control**                                                                                                                                                                                                                                                                                                
  PB                      2364/3220                                      1.37(1.11,1.68)            0.003                        0.107            1.09(0.97,1.22)                                      0.148   0.198   1.15(0.94,1.42)[^c^](#tfn008){ref-type="table-fn"}   0.171   0.033   1.29(1.06,1.57)    0.010   0.266
  HB                      1533/1657                                      1.12(0.82,1.51)            0.485                        0.642            0.91(0.79,1.04)                                      0.149   0.931   0.91(0.80,1.04)                                      0.164   0.717   1.15(0.86,1.56)    0.349   0.656
  *XPC* rs2228001                                                                                                                                                                                                                                                                                                      
  Total                   6176/6955                                      0.99(0.89,1.10)            0.850                        0.343            0.97(0.90,1.05)                                      0.430   0.206   0.97(0.91,1.05)                                      0.470   0.180   1.01(0.91,1.11)    0.869   0.444
  **Ethnicities**                                                                                                                                                                                                                                                                                                      
  Caucasian               1714/1613                                      0.85(0.70,1.05)            0.369                        0.369            0.91(0.78,1.05)                                      0.194   0.608   0.89(0.78,1.03)                                      0.112   0.462   0.90(0.75,1.09)    0.279   0.485
  African                 814/753                                        0.90(0.60,1.35)            0.649                        0.649            0.94(0.77,1.16)                                      0.567   0.308   0.94(0.77,1.14)                                      0.512   0.420   0.93(0.63,1.37)    0.716   0.513
  Asian                   1068/1052                                      1.14(0.87,1.49)            0.196                        0.196            1.01(0.59,1.75)[^c^](#tfn008){ref-type="table-fn"}   0.962   0.004   1.04(0.63,1.71)[^c^](#tfn008){ref-type="table-fn"}   0.894   0.005   1.10(0.86,1.42)    0.446   0.826
  Other                   2580/3537                                      1.04(0.89,1.22)            0.298                        0.298            0.99(0.88,1.10)                                      0.810   0.792   1.00(0.90,1.11)                                      0.998   0.891   1.06(0.92,1.21)    0.453   0.130
  **Source of control**                                                                                                                                                                                                                                                                                                
  PB                      4587/5222                                      0.95(0.84,1.08)            0.441                        0.377            0.95(0.87,1.04)                                      0.258   0.081   0.95(0.88,1.03)[^b^](#tfn007){ref-type="table-fn"}   0.230   0.056   0.98(0.87,1.10)    0.691   0.795
  HB                      1589/1733                                      1.10(0.89,1.35)            0.371                        0.336            1.03(0.89,1.20)                                      0.700   0.738   1.05(0.91,1.21)                                      0.523   0.971   1.09(0.91,1.32)    0.346   0.122
  *XPA* rs1800975                                                                                                                                                                                                                                                                                                      
  Total                   2619/2663                                      0.92(0.65,1.31)            0.649                        0.003            1.07(0.78,1.48)                                      0.663   0.001   1.03(0.74,1.42)                                      0.873   0.000   0.94(0.84,1.06)    0.303   0.190
  Ethnicities                                                                                                                                                                                                                                                                                                          
  Asian                   1407/1409                                      0.82(0.54,1.26)            0.372                        0.018            0.95(0.60,1.51)                                      0.841   0.002   0.91(0.58,1.43)                                      0.686   0.001   0.83(0.70,0.99)    0.039   0.539
  Other                   1212/1254                                      1.22(0.94,1.59)            0.129                        0.255            1.30(1.01,1.66)                                      0.039   0.821   1.27(1.01,1.60)                                      0.046   0.795   1.05(0.89,1.23)    0.585   0.239
  *ERCC1* rs11615                                                                                                                                                                                                                                                                                                      
  Total                   1012/1035                                      1.56(1.17,2.09)            0.003                        0.717            1.31(1.09,1.58)                                      0.005   0.462   1.38(1.15,1.64)                                      0.000   0.781   1.44(1.10,1.90)    0.009   0.634

rs2228000 cases/controls are not include the studies of Smith(b) and Perez-Mayoral

Ph value of Q-test for heterogeneity test.

Random-effects model was used when a P value \< 0.05 for heterogeneity test; otherwise, fixed-effects model was used.

Available data by Tatemichi et al was used in stratified analyses by cancer type, ethnicity and source of control for the recessive model comparison.

PB: population based control studies; HB: hospital based control studies.

Pooled results suggested that *XPC* rs2228000 TT was associated with increased breast cancer risk. In addition, in the Asian population subgroup, *XPC* rs2228000 TT genotype was a risk factor for breast cancer (Table [6](#T6){ref-type="table"}). Similarly, in the population-based studies subgroup, *XPC* rs2228000 TT genotype was correlated with an increased risk of breast cancer (Table [6](#T6){ref-type="table"}). For *XPC* rs2228001, no significant association was found by pooled or subgroup analysis.

For *XPA* rs1800975, there were no significant associations with breast cancer risk in the pooled results or the Asian population subgroup; however, in the other ethnic population subgroup, a weak but significant association with increased breast cancer was observed in both the co-dominant and dominant models (Table [6](#T6){ref-type="table"}). For *ERCC1* rs11615, the pooled results indicated that TT and TT/CT genotype were associated with increased breast cancer risk (Table [6](#T6){ref-type="table"}).

DISCUSSION {#s3}
==========

This case-control association study revealed that *ERCC1* rs11615 (T allele), *XPC* rs2228000 (T allele) and *ERCC2/XPD* rs50872 (T allele) were associated with increased breast cancer risk. Besides, *ERCC1* rs11615 (T allele), and *ERCC2/XPD* rs50872 (T allele) were associated with postmenopausal breast cancer, while *XPC* rs2228000 (T allele) was associated with premenopausal breast cancer.

The *XPC* gene encodes a 940 amino acid protein that forms an XPC-RAD23B complex with RAD23B \[[@R20]\]. *XPC* rs2228000 is a C-to-T transition causing a substitution in codon 499 in exon 8 that changes alanine to valine in the interaction domain of *XPC* with *hHRAD23*. Consistent with previous reports which linked the TT genotype with lower DNA repair capacity (DRC), \[[@R21]\] this study found that T allele (CT/TT) carriers have a higher breast cancer risk. An independent study reported that presence of the *XPC* rs2228000 T allele (CT or TT genotype) was associated with estrogen receptor positive breast cancer \[[@R22]\]. In all, these studies suggest that patients harboring the *XPC* rs2228000 T allele have a higher risk of breast cancer. Furthermore, the significance of this association was confirmed by the result of the meta-analysis.

Our study revealed that *XPC* rs2228001 was not a risk factor for breast cancer, and this was confirmed by our meta-analysis. Our subgroup analysis revealed that postmenopausal females with AC or AC/CC genotype have a lower breast cancer risk. To our knowledge, this is the first study reporting these results, which should be verified by further work.

Postmenopausal females with *XPA* rs1800975 carrying one or two A alleles have a higher breast cancer risk than those with GG genotype, consistent with reports on populations of northern Chinese \[[@R23]\] and South Korean women \[[@R24]\]. On the other hand, a functional study showed that the *XPA* rs1800975 G allele increased promoter activity \[[@R25]\] leading to increased *XPA* protein concentration \[[@R26]\]. Therefore, *XPA* rs1800975 AA genotype was recognized as a risk factor for lung cancer \[[@R27]\]. It is interesting to see contrasting results among different kinds of cancer, suggesting the susceptibility of *XPA* rs1800975 to cancer risk may be dependent on cancer type.

*ERCC1* variant rs11615 (C19007T) is a C\>T synonymous polymorphism in exon 4 (Asn118Asn), converting a high-usage codon AAC to a low-usage codon AAU. This case-control study revealed the susceptibility of carriers of *ERCC1* variant rs11615 to increased risk of breast cancer, consistent with previous observations that *ERCC1* rs11615 was associated with reduced mRNA \[[@R28]\] and protein \[[@R29]\] expression levels, and consequently impaired DNA repair capacity \[[@R28]\]. Therefore, *ERCC1* rs11615 T allele carriers (CT/TT) exhibited reduced *ERCC1* expression and higher breast cancer risk, which was consistent with our results. This association was supported by the pooled results of this meta-analysis and the study carried out on a population in China \[[@R30]\]. Additionally, in our study the increased risk of breast cancer linked to *ERCC1* rs11615 more prominent in postmenopausal females and patients with positive expression of PR and ER, indicating the risk conveyed by this polymorphism to breast cancer in menopausal females \[[@R30]\].

*ERCC2/XPD* rs50872 is a C/T polymorphism in intron 4 of *XPD*. This case-control study linked *ERCC2/XPD* rs50872 to increased breast cancer risk and showed the polymorphism was more prevalent in the patients with tumor size T3-T4, negative lymph node involvement and patients with ER^−^ and PR^−^ expression, which was consistent with the conclusions in a South Korean population \[[@R24]\].

Some limitations of this study should be noted. First, the relatively small sample size may limit the statistical power to find differences among groups and therefore some associations may be missed, particularly in the multiple stratified analyses. Therefore, we carried out a meta-analysis to confirm the results of the case-control study. Second, several potential environmental factors, such as occupational exposure and diet, were not included in this study, which may influence breast cancer risk. Third, patients' clinical outcomes were not traced for the analysis of the predictive value of polymorphisms in the NER pathway. Finally, the polymorphisms included in this study were still limited, and these polymorphisms were selected based on previous knowledge of their potential functional roles in the occurrence of cancers. Analysis of a wider range of polymorphisms would provide more complete information about the associations of NER genes and breast cancer risk.

In conclusion, our study deduced that *ERCC1* rs11615 (CT or CT/TT), *XPC* rs2228000 (TT or CT/TT) and rs50872 (CT or CT/TT) were risk factors associated with increased breast cancer incidence, especially in postmenopausal women. The risk conferred by polymorphisms in NER pathway genes for breast cancer among females with different menopausal status should be evaluated in a larger cohort study.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

For the case-control association study, from January 2008 to January 2015 in Nanjing First Hospital, Nanjing Medical University, China, we enrolled 450 female patients histologically diagnosed with breast cancer, and 430 age-matched healthy females, who visited the same hospital for routine physical examination, were enrolled as non-cancer controls. All participants were from the same geographic region. The clinical characteristics of each subject, including smoking, drinking, and other cancer history, were collected via a questionnaire and written informed consents were obtained from all participants. Participants were enrolled in this study with no limitation for the smoking and drinking or not, and finally, there were less than ten individuals with a history of smoking and drinking, which may be attributed to the lifestyle of Chinese females. We excluded these samples as unrepresentative of the population before genotyping. The protocol of this study was approved by the Institutional Review Board of Nanjing First Hospital.

Genotyping of polymorphisms {#s4_2}
---------------------------

Genotyping was performed as we described previously \[[@R31], [@R32]\]. The genotyping for all the polymorphisms was performed by Sequenom MassARRAY RS1000 according to the standard protocol. Multiplexed SNP MassEXTENDED assay was designed by Sequenom MassARRAY Assay Design 3.0 Software \[[@R33]\]. Finally, data management and analysis were performed by Sequenom Typer 4.0 Software \[[@R33], [@R34]\].

Immunohistochemistry (IHC) assay {#s4_3}
--------------------------------

The expression of ER, PR, and HER-2 in paraffin-embedded tumor tissue samples was evaluated by immunohistochemistry (IHC) assay, as we described previously \[[@R31], [@R32]\].

Meta-analysis of polymorphisms in *XPA* (rs1800975), *XPC* (rs2228000, rs2228001), and *ERCC1* (rs11615) {#s4_4}
--------------------------------------------------------------------------------------------------------

Meta-analysis was performed to confirm the polymorphisms identified as breast cancer risk factors by our case-control study. Four polymorphisms (*XPA* (rs1800975), *XPC* (rs2228000, rs2228001), and *ERCC1* (rs11615)) were evaluated for breast cancer risk using pooled data from this study and available published studies. The *ERCC2/XPD* rs50873 was ruled out for lack of available published data.

To identify relevant studies, we searched PubMed and Embase databases using the keywords 'XPA,\' 'XPC' or 'ERCC1', 'polymorphism,\' and 'breast cancer' (updated to March 31, 2016). The papers were limited to studies on human subjects and published in English. In addition, references listed in any reviews were manually searched to ensure all relevant studies were included. Then, we evaluated the collected publications by screening the titles and abstracts. All studies which matched the following inclusion criteria were retrieved: (i) evaluated at least one of these four polymorphisms (*XPC* rs2228000, rs2228001, *XPA* rs1800975, and *ERCC1* rs11615) and risk of breast cancer; (ii) from a case-control association study; and (iii) with available genotype frequencies.

All data complying with the selection criteria were extracted by two authors (B. H., and T. X.), independently. For each study, the following characteristics were extracted: the first author\'s last name, country of origin, patient ethnicity, the number of genotyped cases and controls, and the result of this case-control study was also applied for the meta-analysis. For the stratified analysis, subgroup analysis was performed according to ethnicity, which were categorized as Caucasian, Asian, and other; those with mixed ethnicities were categorized as others. In addition, subgroup analysis based on the origin of controls was also applied according to the participants of enrolled studies from population or hospital.

Statistical analysis {#s4_5}
--------------------

For the case-control association study, the statistical analysis of genotype distribution was performed by *χ*^2^ test. The risk of polymorphisms was evaluated by odds ratios (OR) and 95% confidence intervals (CIs), which were calculated using a logistic regression model. *P* value \< 0.05 was considered to have statistically significant difference. Software SPSS 11.0 for Windows (SPSS, Chicago, IL, USA) was used for the statistics.

For the meta-analysis, the overall risk associated with a polymorphism to breast cancer was measured by ORs with 95% CIs based on different genetic models \[Rare allele homozygote (RR), heterozygous (WR), and RR+WR *vs*. wild-type homozygote (WW) genotypes\]. Stratified analyses were performed by ethnicity. The *Z* test was performed to calculate the pooled OR, and a *P* value \< 0.05 was considered as significant. The *χ*^2^ based Q statistical test was used to evaluated the heterogeneity across the enrolled studies \[[@R36]\], and a *P* value of heterogeneity (*P* ~h~) \< 0.05 was considered significant. The random-effects model was used when there was marked heterogeneity across all the studies; otherwise, the fixed-effects model was used \[[@R37]\]. All statistical tests for this meta-analysis were performed with STATA version 10.0 (Stata Corporation College Station, TX, USA).

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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